CO7030962A2 - Compuestos terapéuticamente activos y sus métodos de uso - Google Patents

Compuestos terapéuticamente activos y sus métodos de uso

Info

Publication number
CO7030962A2
CO7030962A2 CO14171766A CO14171766A CO7030962A2 CO 7030962 A2 CO7030962 A2 CO 7030962A2 CO 14171766 A CO14171766 A CO 14171766A CO 14171766 A CO14171766 A CO 14171766A CO 7030962 A2 CO7030962 A2 CO 7030962A2
Authority
CO
Colombia
Prior art keywords
methods
active compounds
therapeutically active
therapeutically
compounds
Prior art date
Application number
CO14171766A
Other languages
English (en)
Inventor
Giovanni Cianchetta
Byron Delabarre
Janeta Popovici-Muller
Francesco G Salituro
Jeffrey O Saunders
Jeremy Travins
Shunqi Yan
Tao Guo
Li Zhang
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48744984&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO7030962(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of CO7030962A2 publication Critical patent/CO7030962A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CO14171766A 2012-01-06 2014-08-06 Compuestos terapéuticamente activos y sus métodos de uso CO7030962A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261584214P 2012-01-06 2012-01-06

Publications (1)

Publication Number Publication Date
CO7030962A2 true CO7030962A2 (es) 2014-08-21

Family

ID=48744984

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14171766A CO7030962A2 (es) 2012-01-06 2014-08-06 Compuestos terapéuticamente activos y sus métodos de uso

Country Status (39)

Country Link
US (7) US9732062B2 (es)
EP (3) EP3984997A1 (es)
JP (2) JP6411895B2 (es)
KR (1) KR101893112B1 (es)
CN (6) CN104114543B (es)
AR (1) AR090411A1 (es)
AU (2) AU2013207289B2 (es)
BR (1) BR112014016805B1 (es)
CA (1) CA2860623A1 (es)
CL (1) CL2014001793A1 (es)
CO (1) CO7030962A2 (es)
CR (1) CR20140377A (es)
CY (1) CY1120506T1 (es)
DK (1) DK2800743T3 (es)
EA (1) EA030187B1 (es)
EC (1) ECSP14012726A (es)
ES (2) ES2901430T3 (es)
HK (1) HK1203942A1 (es)
HR (1) HRP20180844T1 (es)
HU (1) HUE038403T2 (es)
IL (1) IL233503B (es)
LT (1) LT2800743T (es)
MX (1) MX358940B (es)
MY (1) MY185206A (es)
NI (1) NI201400073A (es)
NO (1) NO2897546T3 (es)
NZ (2) NZ722582A (es)
PE (1) PE20142098A1 (es)
PH (1) PH12014501561B1 (es)
PL (1) PL2800743T3 (es)
PT (1) PT2800743T (es)
RS (1) RS57401B1 (es)
SG (2) SG11201403878QA (es)
SI (1) SI2800743T1 (es)
TR (1) TR201809228T4 (es)
TW (1) TWI653228B (es)
UA (1) UA117451C2 (es)
WO (1) WO2013102431A1 (es)
ZA (1) ZA201405163B (es)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120121515A1 (en) 2009-03-13 2012-05-17 Lenny Dang Methods and compositions for cell-proliferation-related disorders
KR101712035B1 (ko) 2009-06-29 2017-03-03 아지오스 파마슈티컬스 아이엔씨. 치료용 화합물 및 조성물
EP2525790B1 (en) 2009-10-21 2020-05-27 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
EP3561077B1 (en) 2009-10-21 2022-12-21 Les Laboratoires Servier Methods for cell-proliferation-related disorders
SG194697A1 (en) 2011-05-03 2013-12-30 Agios Pharmaceuticals Inc Pyruvate kinase activators for use in therapy
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
KR101653473B1 (ko) 2012-01-06 2016-09-01 어바이드 테라퓨틱스, 인크. 카르바메이트 화합물 및 그의 제조 및 이용 방법
CN104114543B (zh) * 2012-01-06 2019-03-15 安吉奥斯医药品有限公司 治疗活性化合物及其使用方法
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
JP6385352B2 (ja) 2012-10-15 2018-09-05 アジオス ファーマシューティカルズ， インコーポレイテッド 治療化合物および組成物
BR112016000489A8 (pt) * 2013-07-11 2020-01-07 Agios Pharmaceuticals Inc composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos
CN111087353B (zh) * 2013-07-11 2023-10-24 法国施维雅药厂 治疗活性化合物及其使用方法
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US10376510B2 (en) 2013-07-11 2019-08-13 Agios Pharmaceuticals, Inc. 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015003360A2 (en) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
MX2020011397A (es) 2013-08-02 2022-08-05 Agios Pharmaceuticals Inc Compuestos inhibidores de isocitrato deshidrogenasa 2 (idh2) y el uso de los mismos.
KR102316886B1 (ko) * 2013-08-02 2021-10-19 아지오스 파마슈티컬스 아이엔씨. 치료학적 활성 화합물 및 이의 사용방법
WO2015018060A1 (en) * 2013-08-09 2015-02-12 Agios Pharmaceuticals, Inc. Crystalline forms of therapeutically active compounds and use thereof
TWI651310B (zh) * 2014-02-20 2019-02-21 日商日本煙草產業股份有限公司 三化合物及其醫藥用途
US20170007661A1 (en) * 2014-03-14 2017-01-12 Agios Pharmaceuticals, Inc Pharmaceutical compositions of therapeutically active compounds
JP6564796B2 (ja) 2014-03-14 2019-08-21 アジオス ファーマシューティカルズ， インコーポレイテッド 治療活性化合物の医薬組成物
WO2015144881A1 (en) * 2014-03-28 2015-10-01 Basf Se Diaminotriazine derivatives as herbicides
WO2015155129A1 (en) * 2014-04-07 2015-10-15 Basf Se Diaminotriazine compound
EP2930174A1 (en) * 2014-04-07 2015-10-14 Basf Se Diaminotriazine derivatives as herbicides
LT3447050T (lt) * 2014-09-19 2020-05-11 Forma Therapeutics, Inc. Piridin-2(1h)-ono chinolinono dariniai, kaip mutantinės izocitrato dehidrogenazės inhibitoriai
JP6820836B2 (ja) 2014-09-19 2021-01-27 フォーマ セラピューティクス，インコーポレイテッド 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのフェニルキノリノン誘導体
WO2016044781A1 (en) 2014-09-19 2016-03-24 Forma Therapeutics, Inc. Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors
JP6751081B2 (ja) * 2014-09-19 2020-09-02 フォーマ セラピューティクス，インコーポレイテッド 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのピリジニルキノリノン誘導体
AU2015324158A1 (en) 2014-09-29 2017-04-13 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CN107531675A (zh) * 2015-02-04 2018-01-02 安吉奥斯医药品有限公司 治疗活性化合物及其使用方法
US9771341B2 (en) 2015-03-18 2017-09-26 Abide Therapeutics, Inc. Piperazine carbamates and methods of making and using same
EA038574B1 (ru) * 2015-04-21 2021-09-16 Форма Терапьютикс, Инк. Хинолиноновые производные пиридин-2(1h)-она и фармацевтические композиции на их основе
US9624175B2 (en) 2015-04-21 2017-04-18 Forma Therapeutics, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
WO2016171756A1 (en) * 2015-04-21 2016-10-27 Forma Therapeutics, Inc. Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
WO2016177347A1 (en) * 2015-05-07 2016-11-10 Teligene Ltd Heterocyclic compounds as idh2 inhibitors
MX2017014344A (es) 2015-05-11 2018-04-11 Abide Therapeutics Inc Metodos para el tratamiento de la inflacion o el dolor neuropatico.
EP4344703A1 (en) 2015-06-11 2024-04-03 Agios Pharmaceuticals, Inc. Methods of using pyruvate kinase activators
TWI722004B (zh) * 2015-07-30 2021-03-21 大陸商正大天晴藥業集團股份有限公司 1,3,5-三嗪衍生物及其使用方法
MX365590B (es) * 2015-08-05 2019-06-07 Agios Pharmaceuticals Inc Metodos para preparar 6-(aril o heteroaril)-1,3,5-triazin-2,4-diol es y 6-(aril o heteroaril)-1,3,5-triazin-2,4-diaminas.
ES2862730T3 (es) 2015-10-15 2021-10-07 Celgene Corp Combinación de un inhibidor de isocitrato deshidrogenasa 2 mutante con azacitidina y su uso para el tratamiento de la leucemia mielógena aguda
EA201890968A1 (ru) 2015-10-15 2018-09-28 Аджиос Фармасьютикалз, Инк. Комбинированная терапия для лечения злокачественных новообразований
LT3362066T (lt) 2015-10-15 2022-02-10 Les Laboratoires Servier Sas Kombinuota terapija, skirta piktybinių susirgimų gydymui
EP3362065B1 (en) 2015-10-15 2024-04-03 Les Laboratoires Servier Combination therapy comprising ivosidenib, cytarabine and daunorubicin or idarubicin for treating acute myelogenous leukemia
US9688659B2 (en) * 2015-10-21 2017-06-27 NeuForm Pharmaceuticals, Inc. Deuterated compounds for treating hematologic malignancies, and compositions and methods thereof
KR20180086255A (ko) 2015-12-04 2018-07-30 아지오스 파마슈티컬스 아이엔씨. 악성종양의 치료 방법
CN105399695B (zh) * 2015-12-11 2019-04-19 浙江大学 三嗪类化合物及其制备方法和用途
CN105384702B (zh) * 2015-12-11 2018-04-10 浙江大学 三取代均三嗪类化合物及其制备方法
CN105503754B (zh) * 2015-12-11 2017-11-17 浙江大学 2‑氨基‑4‑苄基‑6‑吗啉‑1,3,5‑三嗪及其制备和应用
WO2017140758A1 (en) 2016-02-19 2017-08-24 Debiopharm International S.A. Derivatives of 2-amino-4-(2-oxazolidinon-3-yl)-pyrimidine fused with a five-membered heteroaromatic ring in 5,6-position which are useful for the treatment of various cancers
US10463753B2 (en) 2016-02-19 2019-11-05 Lundbeck La Jolla Research Center, Inc. Radiolabeled monoacylglycerol lipase occupancy probe
JP6930991B2 (ja) 2016-02-26 2021-09-01 セルジーン コーポレイション 血液学的悪性腫瘍及び固形腫瘍の治療のためのｉｄｈ２阻害剤
CN105753801B (zh) * 2016-03-25 2018-06-01 浙江工业大学 一种均三嗪类化合物的制备方法
CN105820133B (zh) * 2016-03-25 2018-06-05 浙江工业大学 多取代均三嗪类化合物及其制备方法和应用
KR102232614B1 (ko) * 2016-07-21 2021-03-29 난징 산홈 팔마세우티칼 컴퍼니 리미티드 이소시트레이트 탈수소효소 억제제의 화학적 화합물 및 이의 적용
WO2018026894A1 (en) 2016-08-03 2018-02-08 Celgene Corporation Methods of treatment of myelodysplastic syndrome
BR112019004356A2 (pt) 2016-09-07 2019-05-28 Agios Pharmaceuticals Inc composições de comprimido
WO2018053447A1 (en) 2016-09-19 2018-03-22 Abide Therapeutics, Inc. Piperazine carbamates and methods of making and using same
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190105A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
WO2018133856A1 (zh) * 2017-01-22 2018-07-26 正大天晴药业集团股份有限公司 1，3，5-三嗪衍生物的盐及其晶体、它们的制备方法、药物组合物和用途
WO2018204787A1 (en) 2017-05-05 2018-11-08 Memorial Sloan Kettering Cancer Center Methods of treatment of myeloproliferative neoplasm
MX2019015886A (es) 2017-06-30 2020-09-10 Celgene Corp Composiciones y metodos de uso de 2-(4-clorofenil)-n-((2-(2,6-diox opiperidin-3-il)-1-0xoisoindolin-5-il)metil)-2,2-difluoroacetamid a.
CN109265444B (zh) * 2017-07-17 2022-03-11 南京圣和药业股份有限公司 取代的三嗪类idh抑制剂的光学异构体及其应用
CN109467538A (zh) 2017-09-07 2019-03-15 和记黄埔医药（上海）有限公司 环烯烃取代的杂芳环类化合物及其用途
CN110054615B (zh) * 2018-01-19 2021-06-15 南京圣和药业股份有限公司 三嗪类idh抑制剂甲磺酸盐的晶型
CN110054617A (zh) * 2018-01-19 2019-07-26 南京圣和药业股份有限公司 三嗪类化合物、其制备方法及用途
CN110051673B (zh) * 2018-01-19 2022-03-11 南京圣和药业股份有限公司 一种包含三嗪类idh抑制剂的药物组合物及其用途
CN110054616B (zh) * 2018-01-19 2021-11-23 南京圣和药业股份有限公司 三嗪类idh抑制剂的制备方法
US11332453B2 (en) 2018-05-15 2022-05-17 H. Lundbeck A/S MAGL inhibitors
US11013733B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
US11013734B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
US11311527B2 (en) 2018-05-16 2022-04-26 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
EP3720442B1 (en) 2018-05-16 2022-12-28 Forma Therapeutics, Inc. Inhibiting mutant idh-1
US10532047B2 (en) 2018-05-16 2020-01-14 Forma Therapeutics, Inc. Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
KR102328682B1 (ko) * 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
WO2020092915A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid dispersions for treatment of cancer
WO2020092894A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol
US20220017490A1 (en) 2018-11-02 2022-01-20 Celgene Corporation Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof
CN111662275B (zh) * 2019-03-08 2023-08-22 中国药科大学 苯磺酰胺类idh突变体抑制剂、其制备方法和用途
CN111662271B (zh) * 2019-03-08 2023-11-14 中国药科大学 具有idh突变体抑制活性的化合物及其制备方法与应用
WO2020239759A1 (en) 2019-05-27 2020-12-03 Sandoz Ag Amorphous enasidenib in a stabilized form
CN114502537A (zh) * 2019-09-29 2022-05-13 贝达药业股份有限公司 突变型idh2抑制剂及其应用
US20220401450A1 (en) 2019-11-14 2022-12-22 Celgene Corporation Pediatric formulations for treatment of cancer
EP4139288A1 (en) 2020-04-21 2023-03-01 H. Lundbeck A/S Synthesis of a monoacylglycerol lipase inhibitor
CN111592524B (zh) * 2020-05-20 2023-11-17 温州市天聚万迅信息科技有限公司 恩西德尼的制备方法
US20240092802A1 (en) * 2020-10-06 2024-03-21 Kures, Inc. Mu-opioid receptor agonists and uses therefor
US11865079B2 (en) 2021-02-12 2024-01-09 Servier Pharmaceuticals Llc Therapeutically active compounds and their methods of use
AU2022219973A1 (en) * 2021-02-12 2023-09-07 Les Laboratoires Servier Therapeutically active compounds and their methods of use
CN113461660B (zh) * 2021-06-11 2022-08-02 浙江大学 2,4,6-三取代-1,3,5-均三嗪类化合物及制备和应用
WO2023174235A1 (zh) * 2022-03-15 2023-09-21 贝达药业股份有限公司 突变型idh1和idh2抑制剂及其应用
WO2023183520A1 (en) 2022-03-24 2023-09-28 A2A Pharmaceuticals, Inc. Compositions and methods for treating cancer
CN114773320A (zh) * 2022-05-29 2022-07-22 重庆医科大学 1,3,5-三嗪化合物及其制备方法和用途
CN115536637A (zh) * 2022-10-24 2022-12-30 陕西中医药大学 一种均三嗪类衍生物及其合成方法与用途

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2390529A (en) 1942-02-03 1945-12-11 Ernst A H Friedheim Hydrazino-1,3,5-triazino derivatives of substituted phenylarsenic compounds
BE754242A (fr) 1970-07-15 1971-02-01 Geigy Ag J R Diamino-s-triazines et dinitro-s-triazines
US3867383A (en) 1971-03-29 1975-02-18 Ciba Geigy Corp Monoanthranilatoanilino-s-triazines
CH606334A5 (es) 1974-06-21 1978-10-31 Ciba Geigy Ag
JPS58186682A (ja) 1982-04-27 1983-10-31 日本化薬株式会社 セルロ−ス又はセルロ−ス含有繊維材料の染色法
DE3512630A1 (de) 1985-04-06 1986-10-23 Hoechst Ag, 6230 Frankfurt Verfahren zum faerben oder bedrucken von cellulosefasern oder cellulosemischfasern
US5041443A (en) 1989-02-21 1991-08-20 Dainippon Pharmaceutical Co., Ltd. Medicament for treating cerebral insufficiency diseases, novel 2-(1-piperazinyl)-4-phenylcycloalkanopyrimidine derivatives, and process for the production thereof
DE69010232T2 (de) 1989-03-03 1994-12-01 Dainippon Pharmaceutical Co 2-(1-Piperazinyl)-4-phenylcycloalkanpyridin-Derivate, Verfahren zu deren Herstellung und pharmazeutische Zusammensetzungen, die sie enthalten.
EP0466647B1 (de) 1990-07-12 1995-11-29 Ciba-Geigy Ag Verfahren zur photochemischen und thermischen Stabilisierung von Polyamid-Fasermaterialien
JPH0499768A (ja) 1990-08-17 1992-03-31 Dainippon Pharmaceut Co Ltd ４―（４―フェニルピリジン―２―イル）ピペラジン―１―オキシド誘導体
WO1993017009A1 (en) 1992-02-28 1993-09-02 Zenyaku Kogyo Kabushiki Kaisha s-TRIAZINE DERIVATIVE AND REMEDY FOR ESTROGEN-DEPENDENT DISEASES CONTAINING THE SAME AS ACTIVE INGREDIENT
IL115420A0 (en) 1994-09-26 1995-12-31 Zeneca Ltd Aminoheterocyclic derivatives
FR2735127B1 (fr) 1995-06-09 1997-08-22 Pf Medicament Nouvelles piperazines heteroaromatiques utiles comme medicaments.
GB9602166D0 (en) 1996-02-02 1996-04-03 Zeneca Ltd Aminoheterocyclic derivatives
JPH09291034A (ja) 1996-02-27 1997-11-11 Yoshitomi Pharmaceut Ind Ltd 縮合ピリジン化合物およびその医薬としての用途
CN1219168A (zh) 1996-05-20 1999-06-09 达尔文发现有限公司 作为tnf抑制剂和pdc-iv抑制剂的喹啉磺酰胺类化合物
US5984882A (en) 1996-08-19 1999-11-16 Angiosonics Inc. Methods for prevention and treatment of cancer and other proliferative diseases with ultrasonic energy
EP0945446A4 (en) 1996-11-14 1999-12-08 Nissan Chemical Ind Ltd CYANOETHYLMELAMINE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME
US6399358B1 (en) 1997-03-31 2002-06-04 Thomas Jefferson University Human gene encoding human chondroitin 6-sulfotransferase
JPH11158073A (ja) * 1997-09-26 1999-06-15 Takeda Chem Ind Ltd アデノシンａ３拮抗剤
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
UY25842A1 (es) 1998-12-16 2001-04-30 Smithkline Beecham Corp Antagonistas de receptores de il-8
WO2000075129A1 (en) 1999-06-07 2000-12-14 Shire Biochem Inc. Thiophene integrin inhibitors
US6596772B1 (en) 1999-08-27 2003-07-22 Sugen, Inc. Phosphate mimics and methods of treatment using phosphatase inhibitors
JP4688401B2 (ja) 2000-07-03 2011-05-25 関西ペイント株式会社 ガスバリヤー性フィルム
NZ523526A (en) 2000-07-20 2004-10-29 Neurogen Corp Diaryl piperazines as capsaicin receptor ligands
EP1397142A4 (en) 2001-06-19 2004-11-03 Bristol Myers Squibb Co PYRIMIDINE PHOSPHODIESTERASE (PDE) INHIBITORS 7
DE60238066D1 (de) 2001-08-17 2010-12-02 Basf Se Triazinderivate und deren verwendung als sonnenschutzmittel
JP4753336B2 (ja) 2001-09-04 2011-08-24 日本化薬株式会社 新規アリル化合物及びその製法
US7291616B2 (en) * 2001-10-31 2007-11-06 Cell Therapeutics, Inc. Aryl triazines as LPAAT-β inhibitors and uses thereof
US6878196B2 (en) 2002-01-15 2005-04-12 Fuji Photo Film Co., Ltd. Ink, ink jet recording method and azo compound
US20040067234A1 (en) 2002-07-11 2004-04-08 Paz Einat Isocitrate dehydrogenase and uses thereof
ES2575522T3 (es) 2002-07-18 2016-06-29 Janssen Pharmaceutica Nv Inhibidores de quinasas con triazina sustituida
JP2004107220A (ja) 2002-09-13 2004-04-08 Mitsubishi Pharma Corp ＴＮＦ−α産生抑制剤
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
WO2004050033A2 (en) 2002-12-02 2004-06-17 Arqule, Inc. Method of treating cancers
JP4739763B2 (ja) 2002-12-16 2011-08-03 ゲンマブ エー／エス インターロイキン８（ｉｌ−８）に対するヒトモノクローナル抗体
JP2006515883A (ja) 2003-01-10 2006-06-08 スレッシュオールド ファーマシューティカルズ， インコーポレイテッド ２−デオキシグルコースによる癌の処置
US7358262B2 (en) 2003-01-29 2008-04-15 Whitehead Institute For Biomedical Research Identification of genotype-selective anti-tumor agents
WO2004074438A2 (en) 2003-02-14 2004-09-02 Smithkline Beecham Corporation Ccr8 antagonists
WO2004073619A2 (en) 2003-02-14 2004-09-02 Smithkline Beecham Corporation Ccr8 antagonists
EP1689722A2 (en) 2003-10-10 2006-08-16 Bayer Pharmaceuticals Corporation 4-aminopyrimidine derivatives for treatment of hyperproliferative disorders
US20070196395A1 (en) 2003-12-12 2007-08-23 Mackerell Alexander Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain
EP1708712A1 (en) 2003-12-24 2006-10-11 Scios, Inc. Treatment of malignant gliomas with tgf-beta inhibitors
AU2005286592A1 (en) 2004-09-23 2006-03-30 Reddy Us Therapeutics, Inc. Novel pyrimidine compounds, process for their preparation and compositions containing them
WO2006070198A1 (en) 2004-12-30 2006-07-06 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
US20080146570A1 (en) 2005-01-25 2008-06-19 Astrazeneca Ab Chemical Compounds
CA2611728A1 (en) 2005-06-08 2006-12-14 Millennium Pharmaceuticals, Inc. Methods for the identification, assessment, and treatment of patients with cancer therapy
KR20080049767A (ko) 2005-08-26 2008-06-04 라보라뚜와르 세로노 에스. 에이. 피라진 유도체 및 ｐｉ３ｋ 억제제로서의 용도
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
TW200815426A (en) 2006-06-28 2008-04-01 Astrazeneca Ab New pyridine analogues II 333
WO2008070661A1 (en) 2006-12-04 2008-06-12 Neurocrine Biosciences, Inc. Substituted pyrimidines as adenosine receptor antagonists
AU2007333925B2 (en) 2006-12-15 2013-10-31 Nantbio, Inc. Triazine derivatives and their therapeutical applications
JP5450381B2 (ja) * 2007-04-30 2014-03-26 プロメティック・バイオサイエンスィズ・インコーポレーテッド 化合物、そのような化合物を含有する組成物、及びそのような化合物を用いるがん及び自己免疫疾患の治療法
JP2010529193A (ja) 2007-06-11 2010-08-26 ミイカナ セラピューティクス インコーポレイテッド 置換ピラゾール化合物
BRPI0814628B1 (pt) 2007-07-20 2022-04-05 Nerviano Medical Sciences S.R.L. Derivados ativos de indazol substituídos como inibidores da quinase
WO2009027736A2 (en) * 2007-08-27 2009-03-05 Astrazeneca Ab 2,4 diaminopyrimid'lnes for the treatment of myeloproliferative disorders and cancer
AR068764A1 (es) 2007-10-10 2009-12-02 Takeda Pharmaceutical N-piperazin amidas y su uso en medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de faah.
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
GB0805477D0 (en) 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
JP5277685B2 (ja) 2008-03-26 2013-08-28 富士ゼロックス株式会社 電子写真感光体、画像形成装置、プロセスカートリッジ及び画像形成方法
CN101575408B (zh) 2008-05-09 2013-10-30 Mca技术有限公司 用作阻燃剂和光稳定剂的聚三嗪基化合物
FR2932483A1 (fr) 2008-06-13 2009-12-18 Cytomics Systems Composes utiles pour le traitement des cancers.
WO2010007756A1 (ja) 2008-07-14 2010-01-21 塩野義製薬株式会社 Ｔｔｋ阻害作用を有するピリジン誘導体
AU2009288004B2 (en) 2008-09-03 2015-02-05 Duke University Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma
WO2010028179A1 (en) 2008-09-03 2010-03-11 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds as gata modulators
JP2010079130A (ja) 2008-09-29 2010-04-08 Fuji Xerox Co Ltd 電子写真感光体、プロセスカートリッジ、及び画像形成装置
JP2010181540A (ja) 2009-02-04 2010-08-19 Fuji Xerox Co Ltd 電子写真感光体、プロセスカートリッジ、及び画像形成装置
PL2394999T3 (pl) * 2009-02-06 2014-06-30 Nippon Shinyaku Co Ltd Pochodna aminopirazyny i lek
US20120121515A1 (en) 2009-03-13 2012-05-17 Lenny Dang Methods and compositions for cell-proliferation-related disorders
WO2010144338A1 (en) * 2009-06-08 2010-12-16 Abraxis Bioscience, Llc Triazine derivatives and their therapeutical applications
US8261872B2 (en) 2009-06-08 2012-09-11 Clark Equipment Company Work machine having modular ignition switch keypad with latching output
WO2010144404A1 (en) 2009-06-09 2010-12-16 Abraxis Bioscience, Llc Pyridil-triazine inhibitors of hedgehog signaling
CA2765050A1 (en) 2009-06-09 2010-12-16 California Capital Equity, Llc Ureidophenyl substituted triazine derivatives and their therapeutical applications
ES2582535T3 (es) 2009-07-10 2016-09-13 Kirk Promotion Ltd. Dispositivo de articulación de la rodilla
JP5473851B2 (ja) 2009-09-30 2014-04-16 富士フイルム株式会社 高分子フィルム、位相差フィルム、偏光板及び液晶表示装置
EP3561077B1 (en) 2009-10-21 2022-12-21 Les Laboratoires Servier Methods for cell-proliferation-related disorders
EP2525790B1 (en) 2009-10-21 2020-05-27 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
EP2509600B1 (en) 2009-12-09 2017-08-02 Agios Pharmaceuticals, Inc. Therapeutically active compounds for use in the treatment of cancer characterized as having an idh mutation
US20130197106A1 (en) 2010-04-01 2013-08-01 Agios Pharmaceuticals, Inc Methods of identifying a candidate compound
CN103097340B (zh) 2010-07-16 2018-03-16 安吉奥斯医药品有限公司 治疗活性组合物及其使用方法
BR112013013429A2 (pt) 2010-11-29 2017-03-21 Galleon Pharmaceuticals Inc composição, método de prevenção ou tratamento de distúrbio ou doença de controle da respiração, e, método de prevenção de desestabilização ou estabilização do ritmo respiratório
TWI555737B (zh) 2011-05-24 2016-11-01 拜耳知識產權公司 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102659765B (zh) 2011-12-31 2014-09-10 沈阳药科大学 嘧啶及三嗪类化合物的制备方法和应用
KR101653473B1 (ko) 2012-01-06 2016-09-01 어바이드 테라퓨틱스, 인크. 카르바메이트 화합물 및 그의 제조 및 이용 방법
CN104114543B (zh) * 2012-01-06 2019-03-15 安吉奥斯医药品有限公司 治疗活性化合物及其使用方法
JP6228130B2 (ja) 2012-01-19 2017-11-08 アジオス ファーマシューティカルズ， インコーポレイテッド 治療活性化合物およびそれらの使用方法
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
KR20140131955A (ko) 2012-03-09 2014-11-14 카나 바이오사이언스 인코포레이션 신규 트리아진 유도체
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use

Also Published As

Publication number Publication date
PE20142098A1 (es) 2015-01-08
SI2800743T1 (en) 2018-08-31
NI201400073A (es) 2014-12-22
JP2015503571A (ja) 2015-02-02
HK1203942A1 (en) 2015-11-06
US20230250078A1 (en) 2023-08-10
AU2017265096B2 (en) 2019-08-08
US20130190287A1 (en) 2013-07-25
SG10201602862RA (en) 2016-05-30
JP2017075193A (ja) 2017-04-20
LT2800743T (lt) 2018-06-25
AU2017265096A1 (en) 2017-12-14
CR20140377A (es) 2014-11-13
EP3406608B8 (en) 2022-01-19
HUE038403T2 (hu) 2018-10-29
AU2017265096B9 (en) 2019-09-05
DK2800743T3 (en) 2018-06-14
CN108912066A (zh) 2018-11-30
EA030187B1 (ru) 2018-07-31
EA201491330A1 (ru) 2015-04-30
ES2675760T3 (es) 2018-07-12
WO2013102431A1 (en) 2013-07-11
EP2800743A4 (en) 2015-08-26
US20170044139A1 (en) 2017-02-16
SG11201403878QA (en) 2014-08-28
AU2013207289B2 (en) 2017-09-21
TR201809228T4 (tr) 2018-07-23
CN115536635A (zh) 2022-12-30
IL233503A0 (en) 2014-08-31
CN104114543A (zh) 2014-10-22
RS57401B1 (sr) 2018-09-28
MY185206A (en) 2021-04-30
KR101893112B1 (ko) 2018-08-30
US20200079755A1 (en) 2020-03-12
CL2014001793A1 (es) 2014-11-07
BR112014016805B1 (pt) 2019-07-30
CN115521264A (zh) 2022-12-27
IL233503B (en) 2018-07-31
PH12014501561A1 (en) 2014-10-08
HRP20180844T1 (hr) 2018-08-24
US9512107B2 (en) 2016-12-06
UA117451C2 (uk) 2018-08-10
EP2800743A1 (en) 2014-11-12
US20170298045A1 (en) 2017-10-19
TW201329054A (zh) 2013-07-16
NZ722582A (en) 2018-02-23
US9656999B2 (en) 2017-05-23
MX2014008350A (es) 2014-10-06
US20220348554A1 (en) 2022-11-03
EP3406608B1 (en) 2021-09-15
BR112014016805A2 (pt) 2017-06-13
KR20140113712A (ko) 2014-09-24
CA2860623A1 (en) 2013-07-11
US10294215B2 (en) 2019-05-21
CY1120506T1 (el) 2019-07-10
BR112014016805A8 (pt) 2017-07-04
PH12014501561B1 (en) 2014-10-08
US11505538B1 (en) 2022-11-22
AU2013207289A1 (en) 2014-07-31
AU2013207289A2 (en) 2014-07-31
MX358940B (es) 2018-09-10
JP6411895B2 (ja) 2018-10-24
CN107417667A (zh) 2017-12-01
JP6409081B2 (ja) 2018-10-17
CN114933585A (zh) 2022-08-23
US20160318903A1 (en) 2016-11-03
ECSP14012726A (es) 2016-01-29
EP3984997A1 (en) 2022-04-20
NO2897546T3 (es) 2018-01-13
EP2800743B1 (en) 2018-04-04
NZ627096A (en) 2017-02-24
ES2901430T3 (es) 2022-03-22
PT2800743T (pt) 2018-07-04
US9732062B2 (en) 2017-08-15
CN107417667B (zh) 2020-04-10
CN104114543B (zh) 2019-03-15
ZA201405163B (en) 2018-05-30
CN108912066B (zh) 2022-06-24
TWI653228B (zh) 2019-03-11
AR090411A1 (es) 2014-11-12
PL2800743T3 (pl) 2018-09-28
EP3406608A1 (en) 2018-11-28

Similar Documents

Publication Publication Date Title
CO7030962A2 (es) Compuestos terapéuticamente activos y sus métodos de uso
CO7010834A2 (es) Compuestos terapéuticamente activos y sus métodos de uso
IL270347B (en) Therapeutically active compounds and methods of use
CO6870033A2 (es) Compuestos terapéuticos y métodos de uso relacionados
CL2015000640A1 (es) Variantes de hppd y métodos de uso
HK1217948A1 (zh) 治療活性化合物及其使用方法
CR20150380A (es) Compuestos de carbamoilpiridona policíclicos y su uso farmacéutico
HK1204319A1 (en) Therapeutically active compounds and their methods of use
CO6801741A2 (es) Derivados c4-monometil triterpenoides y sus métodos de uso
CO6801774A2 (es) Compuestos de benzotiazol y su uso farmacéutico
HK1223924A1 (zh) 治療活性化合物及其使用方法
CO7020870A2 (es) Anticuerpos anti-htra1 y métodos de uso
CO7000747A2 (es) Anticuerpos anti-lrp5 y métodos de uso
CO7020930A2 (es) Métodos de formación de ésteres pinacólicos de ácido 4–cloro–2– fluoro–3–sustituido–fenilborónico y sus métodos de uso
BR112013022552A2 (pt) compostos de quinazolina substituídos com alcino e métodos de uso
CL2016000235A1 (es) Inhibidores de rorc2 y sus métodos de uso
CO6940436A2 (es) Composicion de control de fitoenfermedades y su uso
CL2014003423A1 (es) Formulaciones antibióticas inyectables y sus métodos de uso.